"BREAK-THROUGH IN CYSTIC FIBROSIS"

[摘要] IT WOULD BE good news indeed if a "break-through through in cystic fibrosis" was really here as has been put forth in the promotional material on Cotazym by Organon, Inc. in an energetic campaign to sell their pancreatic preparation. Uncritical acceptance of unsupported statements in this promotional material would actually be a set-back in the comprehension of present knowledge of cystic fibrosis and the place of pancreatic substitution therapy in the management of patients with this disorder. False hope may be raised in physicians and in the parents of the unfortunate victims of this distressing disease.Though we do not wish to minimize the importance of the pharmaceutical development of an improved pancreatin preparation we believe that presenting Cotazym as a "break-through in cystic fibrosis" is unwarranted and misleading.

[学科分类] 儿科学